Studies have shown that the upregulation of immune checkpoints such as PD-L1, CTLA-4, TIM-3, and LAG3 in glioma helps tumor immune evasion, leading to T cell dysfunction (30–32), suggesting that METTL7B may promote tumor immune evasion by upregulating the expression of immune checkpoints. Here, HAVCR2 is linked to central nervous system cancer.